DAVI

What DAVI does

DÁVI II – Farmacêutica, S.A. (DÁVI) is a Portuguese specialty pharmaceutical laboratory focused on ophthalmology and, to a lesser extent, otorhinolaryngology. Founded in 1915 as the Jaime José da Costa Chemist Shop and renamed DÁVI in 1950, the company has over a century of continuous presence in the Portuguese eye-care market. Since 2007 it has operated as a subsidiary of Lusomedicamenta, which itself was incorporated into the Swedish multinational Recipharm in 2009, giving DÁVI access to multi-continent manufacturing capacity.

The company manufactures and distributes a portfolio of more than 30 products across five categories: prescription drugs (glaucoma treatments such as Zycopt, NEXOTRAV, Visotan and Timolen Forte; antibiotic eye drops XEFLOX and Oftacilox; anti-inflammatories DEMAX and Xafex; otology products Otifix, Oto-Synalar N, Colircusí Gentadexa), OTC drugs (Vitaminoftalmina A, Davilose), medical devices (the preservative-free i-fresh line — ECTO, DUO, REPAIR, TOTAL, GEL — for dry eye), food supplements (Eyecare Omk1, NPO, Retina; i-Clear Vitreo), and cosmetics (Blefarix). Notable technical components include lipid microemulsion formulations, high-molecular-weight hyaluronic acid and trehalose combinations, and Aptar Pharma bottle technology enabling multi-month sterile, preservative-free delivery. Manufacturing is concentrated at a sterile injectable facility in Póvoa de Santo Adrião, with headquarters in Carnaxide.

DÁVI operates a sales-led GTM through Portuguese pharmacies and healthcare providers, combining a dedicated field sales department with licensed-product partnerships and a digital professional-engagement layer (Eyelearning and MGF UpSkills platforms). Its revenue streams combine own-manufactured pharmaceutical sales with licensing/royalty income from third-party product promotion. Geographic operations are concentrated in Portugal with an EU footprint available through the Recipharm group, and distribution is restricted from non-EU countries.

Name

DAVI

Legal name

DÁVI II – Farmacêutica, S.A.

Website

https://davi.pt

Company type

Private

Founded year

1915

Operating status

Operating

Headcount range

11–50 employees

Short description

DÁVI is a Portuguese specialty pharmaceutical laboratory focused on ophthalmology and otorhinolaryngology, manufacturing prescription drugs, medical devices, OTCs, supplements, and cosmetics for Portuguese pharmacies and eye-care professionals. It is a subsidiary of Lusomedicamenta within the Recipharm multinational group.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Ophthalmic Goods Manufacturing (339115)

SIC

Pharmaceutical Preparations (2834), Ophthalmic Goods (3851)

akta.pro primary industry

Eye, Ear & Nasal Care (HLAIADAF)

akta.pro secondary industries

Ophthalmic & Otic Generics (HLAIABAF), Eye, Ear & Nasal Care OTC (Eye Drops, Ear Drops/Wax Removal, Saline Sprays) (CRADAMAG)

Keywords

• Ophthalmic pharmaceuticals
• Sterile eye drops
• Otology treatments
• Eye health supplements
• Medical devices

Headquarters

HQ city

Barcarena

HQ country

Portugal

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical product sales: DÁVI manufactures and sells its own portfolio of ophthalmology and dermatology products including prescription drugs, OTC medicines, medical devices, food supplements, and cosmetics through pharmacy and healthcare provider channels in Portugal.
2. Licensed product commercialization: DÁVI holds partnerships with several pharmaceutical companies for the promotion of third-party products and the sale of products under license.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

DÁVI is a Portuguese pharmaceutical laboratory that develops, manufactures, and sells ophthalmology and dermatology products including prescription drugs, OTC medicines, medical devices, food supplements, and cosmetics. Its manufactured products comprise sterile ophthalmic solutions, eye drops, ophthalmic gels, eye ointments, ear drops, and food supplements for eye health. The products are distributed through pharmacies and healthcare providers in Portugal, addressing glaucoma, dry eye, ocular infections, post-surgical inflammation, allergic conjunctivitis, and otological conditions.

Product overview

DAVI is a Portuguese pharmaceutical laboratory with over 100 years of history, now part of the Recipharm multinational group. The company offers a diversified portfolio of ophthalmology and otolaryngology products divided into five categories: prescription drugs (such as i-fresh ECTO, XEFLOX, Zycopt, Visotan, NEXOTRAV, Otifix, Oto-Synalar N), over-the-counter drugs (such as Vitaminoftalmina A, Davilose), medical devices (the i-fresh line including DUO, GEL, REPAIR, TOTAL for dry eye treatment, plus Eyecare Omk1), food supplements (Eyecare NPO, Eyecare Retina, i-Clear Vitreo), and cosmetics (Blefarix wipes). The company also provides service platforms including Eyelearning for ophthalmology professionals and MGF UpSkills for supporting materials. Products range from antibiotics and anti-inflammatory agents to moisturizing eye drops and nutritional supplements, addressing conditions such as glaucoma, dry eye, infections, and inflammation.

Differentiator

Problem solved

Functional benefit

Products and services

• i-fresh ECTO Sterile ophthalmic solution containing Ectoine 2%, Sodium Hyaluronate 0.1%, and Sodium Carboxymethylcellulose 0.15% for relief of ocular dryness and irritation; preservative-free and phosphate-free.
• Otifix Ear drops suspension containing Dexamethasone 1 mg/ml and Ciprofloxacin 3 mg/ml for treating acute otitis media with tympanostomy tubes (from 6 months) and acute otitis externa (from 1 year).
• Xafex Eye drops suspension containing Loteprednol 5 mg/ml for treating post-surgical ocular inflammation.
• Alergiftalmina Eye drops solution containing Antazoline phosphate 5 mg/ml and Naphazoline hydrochloride 0.5 mg/ml for topical treatment of acute and chronic allergic conjunctivitis.
• Blefarix Sterile single-use pads containing Rosa Centifolia Flower Water, Centaurea Cyanus Flower Water, and Bisabolol for cleaning eyelids and eyelashes, suitable for babies, children, and adults.
• Colircusí Gentadexa Ear or eye drops solution containing Gentamicin 3.0 mg/ml, Dexamethasone sodium phosphate 1.0 mg/ml, and Tetryzoline hydrochloride 0.5 mg/ml for ophthalmic and otologic bacterial infections with inflammation.
• Davilose Eye drops solution containing Hypromellose 5 mg/ml for treating eye irritation and hyposecretion.
• Davilose Forte Eye drops solution containing Hypromellose 10 mg/ml for treating eye irritation and hyposecretion lasting no more than three days.
• Davinefrina Eye drops solution containing Phenylephrine Hydrochloride 100 mg/ml for rapid pupil dilation, reduced capillary congestion, preoperative mydriasis, and temporary reduction of intraocular pressure in open-angle glaucoma.
• DEMAX Preservative-free eye drops solution containing Dexamethasone 1 mg/ml for treating ocular inflammation by inhibiting inflammatory symptoms.
• Eyecare Omk1 Sterile ophthalmic solution containing Citicoline sodium and hyaluronic acid, indicated as an adjunct in the treatment of patients with glaucoma.
• Eyecare NPO Capsules containing 250 mg of citicoline and 0.75 mg of zinc per capsule, contributing to maintaining normal eyesight.
• Eyecare Retina Capsules containing 125 mg of citicoline, 125 mg of alpha-lipoic acid, and 0.75 mg of zinc per capsule, contributing to maintaining normal eyesight.
• i-Clear Vitreo Capsules containing 200 mg hydrolyzed collagen, 100 mg glucosamine, 85 mg red grape dry extract (Vitis vinifera), and 12 mg Vitamin E, contributing to protection of cells against oxidative stress.
• i-fresh DUO Highly effective moisturizing eye drops containing 2% trehalose and 0.25% high-molecular-weight hyaluronic acid for relieving symptoms of moderate and severe dry eye; 6-month shelf life after opening.
• i-fresh GEL Ophthalmic gel containing Dexpanthenol 5% and Carbomer for relief of eye dryness, foreign body sensation, burning, and tired eyes; 8-week shelf life after opening.
• i-fresh REPAIR Eye drops containing 0.15% high-molecular-weight hyaluronic acid, 3% trehalose, and 2% D-Panthenol for regeneration and intensive moisturizing of dry eye surface and post-surgery eye regeneration; 3-month shelf life after opening.
• i-fresh TOTAL Long-acting lipid microemulsion eye drops containing 0.2% hyaluronic acid, 2% trehalose, and 0.1% sacha inchi seed oil for treating and preventing moderate to severe dry eye symptoms; preservative-free with 6-month shelf life.
• Micetinoftalmina colírio Eye drops solution containing Chloramphenicol 5 mg/ml for topical treatment of eye infections caused by chloramphenicol-sensitive micro-organisms.
• Micetinoftalmina pomada Eye ointment containing Chloramphenicol 10 mg/g for topical treatment of external eye infections, conjunctivitis, trachoma, keratitis, blepharitis, dacryocystitis, and corneal ulcers.
• Midriodavi Eye drops solution containing Cyclopentolate Hydrochloride 10 mg/ml for long-term mydriasis and cycloplegia in refraction tests, ophthalmoscopic examinations, cataract surgery, and treatment of iritic conditions.
• NEXOTRAV Preservative-free eye drops solution containing Timolol 5 mg/ml and Travoprost 0.04 mg/ml for treating elevated intraocular pressure in adults that may lead to glaucoma.
• Oftacilox colírio Preserved sterile ophthalmic solution containing Ciprofloxacin 3 mg/ml for treating corneal ulcers and superficial eye infections caused by fluoroquinolone-sensitive microorganisms.
• Oftacilox pomada Sterile ophthalmic ointment containing Ciprofloxacin 3 mg/ml for treating corneal ulcers and superficial eye and surrounding structure infections caused by fluoroquinolone-sensitive microorganisms.
• Óleo-Dermosina Simples Cutaneous suspension containing Zinc Oxide 400 mg/g for treating eczema, various types of dermatitis (particularly acute and exudative stages), and first-degree burns.
• Oto-Synalar N Ear drops solution containing Neomycin 3.5 mg/mL, Polymyxin B 10000 U.I/mL, and Fluocinolone 0.25 mg/mL for treating external otitis and inflammatory conditions responding to steroids when bacterial infection is present.
• Predniftalmina Eye ointment containing Prednisolone 2.5 mg/g and Chloramphenicol 10 mg/g for topical treatment of eye infections requiring corticosteroid for inflammation relief, including allergic conjunctivitis and post-operative inflammation.
• Timolen Forte Eye drops solution containing Timolol maleate 5 mg/ml for reducing intraocular pressure in patients with chronic open-angle glaucoma, aphakic glaucoma, secondary glaucoma, and ocular hypertension.
• Visotan Eye drops solution containing Travoprost 0.03 mg/ml for treating elevated intraocular pressure in adults which may lead to glaucoma, available in 2.5 ml single unit and 3 x 2.5 ml multi-pack formats.
• Vitaminoftalmina A Eye ointment containing Retinyl palmitate 50000 IU/g for treating hyposecretion conjunctival and eye irritation lasting no more than three days.
• XEFLOX Eye drops solution containing Levofloxacin 5 mg/ml, a fluoroquinolone antibiotic for treating bacterial infections affecting the outer surface of the eye including bacterial conjunctivitis in children aged 1 year and over and adults.
• Zycopt Preservative-free eye drops solution containing Timolol 5 mg/ml and Dorzolamide 20 mg/ml for reducing elevated intraocular pressure in glaucoma treatment, available in 5 ml and 2 x 5 ml formats.
• Eyelearning Online platform that brings together all DÁVI services and content, designed for healthcare professionals in ophthalmology.
• MGF UpSkills Support space providing various materials and information in the areas of ophthalmology and otorhinolaryngology for healthcare professionals.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• RecipharmcoreStrategic or Co-development Partner · 1 January 2009Grupo Lusomedicamenta was incorporated into Recipharm, a multinational pharmaceutical company headquartered in Stockholm with factory units across several continents and global operational capacity. DÁVI now operates as part of the Recipharm group.
• LusomedicamentacoreStrategic or Co-development Partner · 1 January 2007In 2007, DÁVI was acquired and incorporated into Lusomedicamenta, a successful pharmaceutical group with great market potential. This acquisition led to DÁVI's current name: DÁVI II – Farmacêutica S.A. Lusomedicamenta also purchased new premises with a sterile injectable unit at Póvoa de Santo Adrião.
• Universities and Medical SocietiesminorStrategic or Co-development PartnerWith a strong focus on innovation and development, DÁVI has partnered with several universities and medical societies for research and development activities in ophthalmology and related fields.
• Pharmaceutical Partner LaboratoriesminorChannel Partner/ Reseller/ DistributorDÁVI has partnerships with several pharmaceutical companies for the promotion of third-party products and the sale of products under license, expanding its product portfolio beyond its own manufacturing.

Scale indicators3 records

Recent moves8 records

Expansion highlights4 records

Regional players

• Dompé: Italian privately-held biopharmaceutical company with ophthalmology and rare disease franchises. Comparable specialty pharma model with European focus, similar mid-sized pharma scale, and overlapping therapeutic areas including ocular surface disease.

Emerging players

• Nicox: French ophthalmology specialty company developing therapeutics for glaucoma and ocular surface diseases. Comparable focus on niche ophthalmic indications and European commercial presence, though smaller and more R&D-focused than DÁVI.

Direct peers

• Horus Pharma: Independent French ophthalmology specialty pharmaceutical company with a comparable portfolio of preservative-free eye drops, dry eye products, and niche ocular therapeutics. Closely mirrors DÁVI's positioning as a European specialty ophthalmology niche player.
• Laboratoires Théa: French family-owned specialty ophthalmology pharmaceutical company with a similar focus on prescription eye drops, dry eye products, and surgical ophthalmic care across European markets. Highly comparable in product mix, distribution model, and niche pharmaceutical positioning to DÁVI.

Broad incumbents

• Alcon: Global ophthalmology leader offering surgical and vision care products across pharmaceuticals, devices, and consumer eye care. Competes with DÁVI in glaucoma drops, anti-infectives, dry eye, and surgical eye care, but at vastly larger scale and broader geographic footprint.
• Santen Pharmaceutical: Japanese specialty ophthalmology company focused on prescription pharmaceuticals for glaucoma, dry eye, and ocular inflammation. Comparable therapeutic categories and preservative-free formulation focus, though Santen operates globally with significantly larger scale.
• Bausch + Lomb: Global ophthalmic pharmaceuticals, surgical devices, and consumer vision care business under Bausch Health. Directly competes with DÁVI across prescription ophthalmology categories (glaucoma, anti-infectives, anti-inflammatories) and OTC dry eye products, with established global distribution.
• Allergan (AbbVie): AbbVie's Allergan Aesthetics and Eye Care division markets leading ophthalmology brands including Lumigan (travoprost) and Restasis. Directly competes with DÁVI's glaucoma portfolio (Visotan, NEXOTRAV, Zycopt) and dry eye franchise across major markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/davi-farmaceutica

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DAVI